Select Trial Semaglutide 2024. A look at the select trial apr 03, 2024 | melody hermel, md ; At the forefront of this evolution is the select (semaglutide effects on cardiovascular outcomes in people with overweight or obesity) trial, a pivotal study.
The select trial extends findings from previous trials, which demonstrated cardiovascular benefit in diabetes mellitus (dm), to those without dm. At the forefront of this evolution is the select (semaglutide effects on cardiovascular outcomes in people with overweight or obesity) trial, a pivotal study.
Who To Select For Treatment With Semaglutide:
A look at the select trial apr 03, 2024 | melody hermel, md ;
The Select Trial Extends Findings From Previous Trials, Which Demonstrated Cardiovascular Benefit In Diabetes Mellitus (Dm), To Those Without Dm.
Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the select trial.
Semaglutide Will Be Injected Into A Skin Fold, In The Stomach, Thigh Or Upper Arm Once A Week At The Same Day Of The Week (To The Extent Possible) Throughout The Trial.
Images References :
A Look At The Select Trial Apr 03, 2024 | Melody Hermel, Md ;
Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.
Semaglutide And Cardiovascular Outcomes In Patients With Overweight Or Obesity And Cardiovascular Disease Who Do Not Have Diabetes:
The select trial extends findings from previous trials, which demonstrated cardiovascular benefit in diabetes mellitus (dm), to those without dm.
At The Forefront Of This Evolution Is The Select (Semaglutide Effects On Cardiovascular Outcomes In People With Overweight Or Obesity) Trial, A Pivotal Study.